<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Poolbeg Pharma Plc — News on 6ix</title>
<link>https://6ix.com/company/poolbeg-pharma-plc</link>
<description>Latest news and press releases for Poolbeg Pharma Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 11 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/poolbeg-pharma-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835eb0a78dffbe2df12a7ec.webp</url>
<title>Poolbeg Pharma Plc</title>
<link>https://6ix.com/company/poolbeg-pharma-plc</link>
</image>
<item>
<title>POLB 001 CRS patent granted in Canada</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-crs-patent-granted-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-crs-patent-granted-in-canada</guid>
<pubDate>Mon, 11 May 2026 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has been granted a patent in Canada for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) treatment, strengthening its global intellectual property portfolio. This patent, which covers the use of any p38 MAPK inhibitor, including POLB 001, for preventing CRS, follows a similar grant in Australia and was expedited through the Patent Prosecution Highway. The company's IP now extends to both cancer immunotherapy-induced CRS and severe influenza across mult</description>
</item>
<item>
<title>Results for the year ended 31 December 2025</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/results-for-the-year-ended-31-december-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/results-for-the-year-ended-31-december-2025-18</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma plc reported its audited results for the year ended December 31, 2025, highlighting a cash balance of £7.7 million, sufficient funding through to 2027, and gross proceeds of £4.865 million raised in an oversubscribed June 2025 fundraise. The company is progressing constructive partnering discussions, anticipating strong potential from its clinical trials, with interim data from the POLB 001 TOPICAL trial expected in the summer. Significant progress was made on POLB 001, including </description>
</item>
<item>
<title>MHRA grants CTA for the POLB 001 TOPICAL trial</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/mhra-grants-cta-for-the-polb-001-topical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/mhra-grants-cta-for-the-polb-001-topical-trial</guid>
<pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma plc has received Clinical Trial Authorisation from the MHRA for its POLB 001 TOPICAL trial, which is on track to deliver interim data this summer, and independent research indicates a multi-billion-dollar peak sales potential in the United States for POLB 001, a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome. The trial will involve approximately 30 patients and has expanded to six UK sites, with patient screening commencing shortly. The p</description>
</item>
<item>
<title>Significant milestone for Poolbeg's IP portfolio</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/significant-milestone-for-poolbegs-ip-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/significant-milestone-for-poolbegs-ip-portfolio</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has announced a significant milestone with the grant of its first patent for cancer immunotherapy-induced Cytokine Release Syndrome (CRS) by IP Australia, covering the use of p38 MAPK inhibitors, including POLB 001, for prevention. This patent strengthens the company's global intellectual property portfolio and enhances the future value and partnership appeal of POLB 001, with interim data from the TOPICAL trial expected in summer 2026. The company is actively pursuing patent </description>
</item>
<item>
<title>Appointment of Dr Adrian Kilcoyne to SAB</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/appointment-of-dr-adrian-kilcoyne-to-sab</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/appointment-of-dr-adrian-kilcoyne-to-sab</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>Poolbeg Pharma plc has announced the appointment of Dr. Adrian Kilcoyne to its Scientific Advisory Board, bringing over 20 years of clinical expertise in oncology and immunology drug development, with a particular focus on haematological malignancies, T-cell therapies, and Cytokine Release Syndrome. Dr. Kilcoyne's extensive background includes leadership roles at Cellectis SA, Celularity Inc., and Humanigen Inc., as well as experience at major pharmaceutical companies like AstraZeneca and Roche.</description>
</item>
<item>
<title>Notification of Major Holdings</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/notification-of-major-holdings-63</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/notification-of-major-holdings-63</guid>
<pubDate>Mon, 09 Feb 2026 15:13:00 GMT</pubDate>
<description>Michael Kelly has acquired a major holding in Poolbeg Pharma PLC, increasing his voting rights to 6.14% from a previous 5.03%. This acquisition, which occurred on February 3, 2026, resulted in Mr. Kelly holding 43,314,547 voting rights. The notification was made to the issuer on February 9, 2026.
Disclaimer*</description>
</item>
<item>
<title>POLB 001 LPS Challenge Trial Paper Published</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-lps-challenge-trial-paper-published</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-lps-challenge-trial-paper-published</guid>
<pubDate>Wed, 28 Jan 2026 07:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has announced the publication of peer-reviewed data from its POLB 001 LPS challenge trial in Frontiers in Immunology, confirming that POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment, including neutrophils by 72.4%-81.5% and TNF by 35.3%-65.1%, while being safe and well-tolerated across all dose levels. The study validates POLB 001's potent inhibition of p38 MAPK driven cytokine responses and supports its potential to prevent cancer immuno</description>
</item>
<item>
<title>Exercise of Options & Total Voting Rights</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/exercise-of-options-and-total-voting-rights-27</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/exercise-of-options-and-total-voting-rights-27</guid>
<pubDate>Tue, 27 Jan 2026 14:30:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has announced the issuance of 7,903,778 new ordinary shares following the exercise of options by former employees. These new shares are expected to be admitted to trading on AIM on February 3, 2026. Following this admission, the Company's total number of ordinary shares in issue and total voting rights will be 705,103,778. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency R</description>
</item>
<item>
<title>Letter to Shareholders – 2025 a year of progress</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/letter-to-shareholders-2025-a-year-of-progress</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/letter-to-shareholders-2025-a-year-of-progress</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>Poolbeg Pharma plc reported significant progress in 2025, highlighted by an oversubscribed £4.865 million fundraise in June, extending its cash runway into 2027 with a £10.0 million cash balance as of June 30, 2025. The company is advancing its POLB 001 TOPICAL trial, which has secured teclistamab from Johnson & Johnson at no cost and is set to begin with interim data expected in summer 2026. Additionally, topline data for its oral GLP-1 program in obese subjects is anticipated in the first half</description>
</item>
<item>
<title>POLB 001 to feature in CRS research programme</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-to-feature-in-crs-research-programme</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-to-feature-in-crs-research-programme</guid>
<pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
<description>Poolbeg Pharma plc announced that its POLB 001 TOPICAL trial will be part of the RISE research program, focused on cancer immunotherapy-induced cytokine release syndrome (CRS), a significant bottleneck for advanced cancer treatments. Poolbeg will serve as the lead business partner alongside Johnson & Johnson and others in this initiative, which is supported by a £3.4 million Medical Research Council grant. The program will not affect the delivery of data from the POLB 001 clinical trial, expecte</description>
</item>
<item>
<title>POLB 001 European Patent granted</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-european-patent-granted</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-european-patent-granted</guid>
<pubDate>Thu, 20 Nov 2025 07:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has been granted a European patent for POLB 001, a p38 MAP kinase inhibitor, strengthening its intellectual property portfolio for the treatment of severe influenza and cancer immunotherapy-induced Cytokine Release Syndrome (CRS), a market estimated at over US$10 billion. This patent enhances the value and appeal of POLB 001 to potential partners by covering its use in these significant therapeutic areas.
Disclaimer*</description>
</item>
<item>
<title>Interim Results for the six months to 30 June 2025</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/interim-results-for-the-six-months-to-30-june-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/interim-results-for-the-six-months-to-30-june-2025-4</guid>
<pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC announced its unaudited interim results for the six months to 30 June 2025, highlighting a strong financial position with a cash balance of £10.0 million, which includes £4.865 million gross proceeds from an oversubscribed fundraise. This extends the cash runway into 2027, supporting key clinical milestones. The loss for the period amounted to £2.2 million, which comprised of R&D expenses of £0.5 million and administrative expenses of £2.0 million. The company's total equity s</description>
</item>
<item>
<title>POLB 001 Phase 2a Trial Update</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-phase-2a-trial-update</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/polb-001-phase-2a-trial-update</guid>
<pubDate>Thu, 25 Sep 2025 06:00:00 GMT</pubDate>
<description>Poolbeg Pharma PLC has appointed Accelerating Clinical Trials Limited (ACT) to conduct the Phase 2a trial for POLB 001. The company has also secured the supply of an approved bispecific antibody drug for the trial at no cost. The Phase 2a trial, titled TOPICAL, will involve approximately 30 relapsed/refractory multiple myeloma patients. Interim data from the trial is anticipated in summer 2026. The company's cash runway extends into 2027. Independent research has identified a market opportunity </description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/directorpdmr-shareholding-346</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/directorpdmr-shareholding-346</guid>
<pubDate>Wed, 25 Jun 2025 07:00:00 GMT</pubDate>
<description>Director/PDMR Shareholding.</description>
</item>
<item>
<title>Results of GM and AGM Meetings</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/results-of-gm-and-agm-meetings</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/results-of-gm-and-agm-meetings</guid>
<pubDate>Mon, 23 Jun 2025 13:57:00 GMT</pubDate>
<description>Results of GM and AGM Meetings.</description>
</item>
<item>
<title>FDA Orphan Drug Designation granted for POLB 001</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/fda-orphan-drug-designation-granted-for-polb-001</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/fda-orphan-drug-designation-granted-for-polb-001</guid>
<pubDate>Tue, 27 May 2025 06:01:00 GMT</pubDate>
<description>FDA Orphan Drug Designation granted for POLB 001.</description>
</item>
<item>
<title>Annual Report, AGM Notice & Circular</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/annual-report-agm-notice-and-circular</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/annual-report-agm-notice-and-circular</guid>
<pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
<description>Annual Report, AGM Notice & Circular.</description>
</item>
<item>
<title>Result of upsized oversubscribed BookBuild Offer</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/result-of-upsized-oversubscribed-bookbuild-offer</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/result-of-upsized-oversubscribed-bookbuild-offer</guid>
<pubDate>Fri, 23 May 2025 06:00:00 GMT</pubDate>
<description>Result of upsized oversubscribed BookBuild Offer.</description>
</item>
<item>
<title>Increase of BookBuild Offer</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/increase-of-bookbuild-offer</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/increase-of-bookbuild-offer</guid>
<pubDate>Thu, 22 May 2025 12:44:00 GMT</pubDate>
<description>Increase of BookBuild Offer.</description>
</item>
<item>
<title>Result of Placing and Notice of General Meeting</title>
<link>https://6ix.com/company/poolbeg-pharma-plc/news/result-of-placing-and-notice-of-general-meeting-6</link>
<guid isPermaLink="true">https://6ix.com/company/poolbeg-pharma-plc/news/result-of-placing-and-notice-of-general-meeting-6</guid>
<pubDate>Tue, 20 May 2025 11:26:00 GMT</pubDate>
<description>Result of Placing and Notice of General Meeting.</description>
</item>
</channel>
</rss>